Evidence map›Paper›PMID 39913870›Full record

ArticleJournal of medicinal chemistry2025

Oxazole-Based Ferroptosis Inhibitors with Promising Properties to Treat Central Nervous System Diseases.

Camilla Scarpellini, Greta Klejborowska, Caroline Lanthier, Ariane Toye, Karolina Musiałek, Emily Van San, Magali Walravens, Maya Berg, Behrouz Hassannia, Pieter Van der Veken and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Oxazole-Based Molecules: Recent Advances on Biological Activities.Current topics in medicinal chemistry · 2026
    Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Camilla ScarpelliniLaboratory of Medicinal Chemistry, Department of Pharmaceutical Sciences, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, University of Antwerp, Antwerp 2610, Belgium.ORCID 0000-0002-1860-6532
Greta KlejborowskaLaboratory of Medicinal Chemistry, Department of Pharmaceutical Sciences, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, University of Antwerp, Antwerp 2610, Belgium.ORCID 0000-0001-9365-4238
Caroline LanthierLaboratory of Medicinal Chemistry, Department of Pharmaceutical Sciences, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, University of Antwerp, Antwerp 2610, Belgium.
Ariane ToyeLaboratory of Medicinal Chemistry, Department of Pharmaceutical Sciences, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, University of Antwerp, Antwerp 2610, Belgium.
Karolina MusiałekLaboratory of Medicinal Chemistry, Department of Pharmaceutical Sciences, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, University of Antwerp, Antwerp 2610, Belgium.ORCID 0009-0005-0187-170X
Emily Van SanCell Death Signaling Lab, Department of Biomedical Sciences, University of Antwerp, Antwerp 2610, Belgium.
Magali WalravensCell Death Signaling Lab, Department of Biomedical Sciences, University of Antwerp, Antwerp 2610, Belgium.
Maya BergInfla-Med Centre of Excellence, University of Antwerp, Antwerp 2610, Belgium.
Behrouz HassanniaCell Death Signaling Lab, Department of Biomedical Sciences, University of Antwerp, Antwerp 2610, Belgium.
Pieter Van der VekenLaboratory of Medicinal Chemistry, Department of Pharmaceutical Sciences, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, University of Antwerp, Antwerp 2610, Belgium.ORCID 0000-0003-1208-3571
Hans De WinterLaboratory of Medicinal Chemistry, Department of Pharmaceutical Sciences, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, University of Antwerp, Antwerp 2610, Belgium.ORCID 0000-0002-4450-7677
Tom Vanden BergheCell Death Signaling Lab, Department of Biomedical Sciences, University of Antwerp, Antwerp 2610, Belgium.
Koen AugustynsLaboratory of Medicinal Chemistry, Department of Pharmaceutical Sciences, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, University of Antwerp, Antwerp 2610, Belgium.ORCID 0000-0002-5203-4339

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ferroptosis plays an important role in the occurrence and development of many diseases, including neurodegenerative diseases. Thus, ferroptosis inhibitors able to cross the blood-brain barrier may have therapeutic potential. The best ferroptosis inhibitors so far are lipophilic radical trapping antioxidants (RTAs) that block lipid peroxidation in membranes. Several generations of ferrostatins have been synthesized, among which

Indexed as

FerroptosisOxazolesAnimalsAntioxidantsBlood-Brain BarrierBrainCentral Nervous System DiseasesHumansMaleMiceRatsStructure-Activity RelationshipAntioxidantsOxazoles

Identifiers

PMID39913870
PMCPMC11874020

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.